229 related articles for article (PubMed ID: 8541230)
1. Differential effects of 1,25-dihydroxyvitamin D3-analogs on osteoblast-like cells and on in vitro bone resorption.
van den Bemd GJ; Pols HA; Birkenhäger JC; Kleinekoort WM; van Leeuwen JP
J Steroid Biochem Mol Biol; 1995 Dec; 55(3-4):337-46. PubMed ID: 8541230
[TBL] [Abstract][Full Text] [Related]
2. Antiestrogens inhibit in vitro bone resorption stimulated by 1,25-dihydroxyvitamin D3 and the vitamin D3 analogs EB1089 and KH1060.
Vink-van Wijngaarden T; Birkenhäger JC; Kleinekoort WM; van den Bemd GJ; Pols HA; van Leeuwen JP
Endocrinology; 1995 Feb; 136(2):812-5. PubMed ID: 7835315
[TBL] [Abstract][Full Text] [Related]
3. Evidence for the functional involvement of protein kinase C in the action of 1,25-dihydroxyvitamin D3 in bone.
van Leeuwen JP; Birkenhäger JC; van den Bemd GJ; Buurman CJ; Staal A; Bos MP; Pols HA
J Biol Chem; 1992 Jun; 267(18):12562-9. PubMed ID: 1320001
[TBL] [Abstract][Full Text] [Related]
4. 22-Oxacalcitriol: dissection of 1,25(OH)2D3 receptor-mediated and Ca2+ entry-stimulating pathways.
Farach-Carson MC; Abe J; Nishii Y; Khoury R; Wright GC; Norman AW
Am J Physiol; 1993 Nov; 265(5 Pt 2):F705-11. PubMed ID: 8238551
[TBL] [Abstract][Full Text] [Related]
5. Effects of the vitamin D3 analog 1 alpha, 25-dihydroxyvitamin D3-3 beta-bromoacetate on rat osteosarcoma cells: comparison with 1 alpha, 25-dihydroxyvitamin D3.
Van Auken M; Buckley D; Ray R; Holick MF; Baran DT
J Cell Biochem; 1996 Dec; 63(3):302-10. PubMed ID: 8913881
[TBL] [Abstract][Full Text] [Related]
6. Evidence for coordinated regulation of osteoblast function by 1,25-dihydroxyvitamin D3 and parathyroid hormone.
van Leeuwen JP; Birkenhäger JC; van den Bemd GC; Pols HA
Biochim Biophys Acta; 1996 Jun; 1312(1):54-62. PubMed ID: 8679716
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of vitamin D analogs as therapeutic agents for prostate cancer.
Chen TC; Holick MF; Lokeshwar BL; Burnstein KL; Schwartz GG
Recent Results Cancer Res; 2003; 164():273-88. PubMed ID: 12899529
[TBL] [Abstract][Full Text] [Related]
8. The activity of 22-oxacalcitriol in osteoblast-like (ROS 17/2.8) cells.
Pernalete N; Mori T; Nishii Y; Slatopolsky E; Brown AJ
Endocrinology; 1991 Aug; 129(2):778-84. PubMed ID: 1649745
[TBL] [Abstract][Full Text] [Related]
9. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.
Skowronski RJ; Peehl DM; Feldman D
Endocrinology; 1995 Jan; 136(1):20-6. PubMed ID: 7530193
[TBL] [Abstract][Full Text] [Related]
10. Regulation of osteocalcin production and bone resorption by 1,25-dihydroxyvitamin D3 in mouse long bones: interaction with the bone-derived growth factors TGF-beta and IGF-I.
Staal A; Geertsma-Kleinekoort WM; Van Den Bemd GJ; Buurman CJ; Birkenhäger JC; Pols HA; Van Leeuwen JP
J Bone Miner Res; 1998 Jan; 13(1):36-43. PubMed ID: 9443788
[TBL] [Abstract][Full Text] [Related]
11. Biologic activity of dihydroxylated 19-nor-(pre)vitamin D3.
Bouillon R; Sarandeses LA; Allewaert K; Zhao J; Mascareñas JL; Mouriño A; Vrielynck S; de Clercq P; Vandewalle M
J Bone Miner Res; 1993 Aug; 8(8):1009-15. PubMed ID: 8213251
[TBL] [Abstract][Full Text] [Related]
12. Nongenomic actions of 1,25-dihydroxyvitamin D3 in rat osteosarcoma cells: structure-function studies using ligand analogs.
Farach-Carson MC; Sergeev I; Norman AW
Endocrinology; 1991 Oct; 129(4):1876-84. PubMed ID: 1655387
[TBL] [Abstract][Full Text] [Related]
13. 1,25(OH)2-16ene-vitamin D3 is a potent antileukemic agent with low potential to cause hypercalcemia.
Jung SJ; Lee YY; Pakkala S; de Vos S; Elstner E; Norman AW; Green J; Uskokovic M; Koeffler HP
Leuk Res; 1994 Jun; 18(6):453-63. PubMed ID: 8207963
[TBL] [Abstract][Full Text] [Related]
14. New 19-nor-(20S)-1alpha,25-dihydroxyvitamin D3 analogs strongly stimulate osteoclast formation both in vivo and in vitro.
Sato M; Nakamichi Y; Nakamura M; Sato N; Ninomiya T; Muto A; Nakamura H; Ozawa H; Iwasaki Y; Kobayashi E; Shimizu M; DeLuca HF; Takahashi N; Udagawa N
Bone; 2007 Feb; 40(2):293-304. PubMed ID: 17070129
[TBL] [Abstract][Full Text] [Related]
15. Demonstration that 1 beta,25-dihydroxyvitamin D3 is an antagonist of the nongenomic but not genomic biological responses and biological profile of the three A-ring diastereomers of 1 alpha,25-dihydroxyvitamin D3.
Norman AW; Bouillon R; Farach-Carson MC; Bishop JE; Zhou LX; Nemere I; Zhao J; Muralidharan KR; Okamura WH
J Biol Chem; 1993 Sep; 268(27):20022-30. PubMed ID: 8397195
[TBL] [Abstract][Full Text] [Related]
16. Nonhypercalcemic 1,25-(OH)2D3 analogs potently induce the human osteocalcin gene promoter stably transfected into rat osteosarcoma cells (ROSCO-2).
Morrison NA; Eisman JA
J Bone Miner Res; 1991 Aug; 6(8):893-9. PubMed ID: 1785378
[TBL] [Abstract][Full Text] [Related]
17. The effects of 1,25-dihydroxyvitamin D3 and dexamethasone on rat osteoblast-like primary cell cultures: receptor occupancy and functional expression patterns for three different bioresponses.
Chen TL; Hauschka PV; Cabrales S; Feldman D
Endocrinology; 1986 Jan; 118(1):250-9. PubMed ID: 3000737
[TBL] [Abstract][Full Text] [Related]
18. Affinity of MC 903 for 1,25-dihydroxyvitamin D receptor and its effects on the synthesis of osteocalcin in human osteosarcoma cells.
Valaja T; Mahonen A; Pirskanen A; Mäenpää PH
Biochem Pharmacol; 1990 Oct; 40(8):1827-32. PubMed ID: 2173591
[TBL] [Abstract][Full Text] [Related]
19. Vitamin D analogs: new therapeutic agents for the treatment of squamous cancer and its associated hypercalcemia.
Yu J; Papavasiliou V; Rhim J; Goltzman D; Kremer R
Anticancer Drugs; 1995 Feb; 6(1):101-8. PubMed ID: 7756673
[TBL] [Abstract][Full Text] [Related]
20. The effects of MC903 on 1,25-(OH)2D3 receptor binding, 24-hydroxylase activity and in vitro bone resorption.
Pols HA; Birkenhäger JC; Schilte JP; Bos MP; van Leeuwen JP
Bone Miner; 1991 Aug; 14(2):103-11. PubMed ID: 1655130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
